Solid Biosciences (SLDB) Other financing activities (2017 - 2026)
Quarterly results put Other financing activities at $12.9 million for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $12.9 million (up 4406.99% YoY), and the annual figure for FY2024 was $5.1 million, changed.
Solid Biosciences has reported Other financing activities over the past 5 years, most recently at $12.9 million for Q1 2026.
- Other financing activities reached $12.9 million in Q1 2026 per SLDB's latest filing, up from $286000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $12.9 million in Q1 2026 and bottomed at $286000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.89 Mn |
| Mar 31, 2026 | 12.89 Mn |
| Jun 30, 2024 | 286,000.00 |
| Jun 30, 2024 | 286,000.00 |
| Mar 31, 2024 | 4.83 Mn |
| Mar 31, 2024 | 4.83 Mn |
| Dec 31, 2019 | 287,000.00 |
| Dec 31, 2019 | 287,000.00 |
| Jun 30, 2018 | 193,000.00 |
| Jun 30, 2018 | 193,000.00 |
| Mar 31, 2018 | 1.98 Mn |
| Mar 31, 2018 | 1.98 Mn |
| Dec 31, 2017 | 1.25 Mn |
| Dec 31, 2017 | 1.25 Mn |
| Sep 30, 2017 | 943,000.00 |
| Sep 30, 2017 | 943,000.00 |
| Jun 30, 2017 | 58,000.00 |
| Jun 30, 2017 | 58,000.00 |
| Mar 31, 2017 | 178,000.00 |
| Mar 31, 2017 | 178,000.00 |